|
|
Article: Angiotech Pharmaceuticals, Inc. - New study shows that Zilver(R) PTX(TM) effectively treats blockages in critical thigh artery.
- Article from:
- PR Newswire
- Article date:
- April 15, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
VANCOUVER, April 14 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. today announced its corporate partner, Cook Medical, reported data on two-year follow up that showed that 82 percent of patients who were treated with Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent (DES) were free from reintervention at two-year follow up. The Zilver PTX Registry study, involving 792 patients from across the world, is assessing the safety and efficacy of the Zilver PTX in treating PAD. The most recent results were reported at the 31st International Symposium: Charing Cross Controversies Challenges Consensus.
"These results are extremely encouraging as ...